Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.

Q2 Medicine

HIV Clinical Trials Pub Date : 2015-08-01 Epub Date: 2015-07-02 DOI:10.1179/1528433614Z.0000000017

Benjamin Young, Kathleen E Squires, Karen Tashima, Keith Henry, Stefan Schneider, Anthony LaMarca, Henry H Zhao, Lisa L Ross, Mark S Shaefer

引用次数: 3

查看原文本刊更多论文

在接受阿扎那韦/利托那韦和阿巴卡韦/拉米夫定或简化为未增强阿扎那韦/阿巴卡韦/拉米夫定治疗的hiv -1感染受试者144周内的肾小球滤过率估计。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

HIV Clinical Trials 医学-传染病学

CiteScore

1.76

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： HIV Clinical Trials is devoted exclusively to presenting information on the latest developments in HIV/AIDS clinical research. This journal enables readers to obtain the most up-to-date, innovative research from around the world.